NICE Rejects Use of Novartis’ Aimovig for Preventing Migraine

The UK’s National Institute for Health and Care Excellence decided to shoot down Novartis’ Aimovig (erenumab) for preventing migraines in adults who have at least four migraine days per year.

The recommendation was based on clinical data which showed uncertainty about whether erenumab is more effective than botulinum toxin type A.

NICE determined that if erenumab only works as well as botulinum toxin type A, cost-effectiveness estimates are much higher than what the agency considers an acceptable use of National Health Service resources.